Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VISEN PharmaceuticalsHKSE:02561 7 PB Ratio is 2.93 as of Aug. 29, 2026, which is 10% below its 10-year median of 3.25. GuruFocus rates HKSE:02561 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 918 Drug Manufacturers companies, VISEN Pharmaceuticals ranks worse than 61.98% on this metric.
The historical rank and industry rank for VISEN Pharmaceuticals's PB Ratio or its related term are showing as below:
HKSE:02561'
s PB Ratio Range Over the Past 10 Years
Min: 2.47 Med: 3.25 Max: 4.89
Current: 2.93
During the past 4 years, VISEN Pharmaceuticals's highest PB Ratio was 4.89. The lowest was 2.47. And the median was 3.25.
HKSE:02561's PB Ratio is ranked worse than 61.98% of 918
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs HKSE:02561: 2.93
During the past 12 months, VISEN Pharmaceuticals's average Book Value Per Share Growth Rate was -23.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 3.10% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of VISEN Pharmaceuticals was 3.10% per year. The lowest was 3.10% per year. And the median was 3.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, VISEN Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VISEN Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, VISEN Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where VISEN Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
VISEN Pharmaceuticals (HKSE:02561) has a PB Ratio of 2.93 as of Aug. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on VISEN Pharmaceuticals and its competitors. This is 10% below median its historical median of 3.25. Over the past decade, VISEN Pharmaceuticals' PB Ratio has ranged from 2.47 to 4.89. According to the industry distribution chart, VISEN Pharmaceuticals ranks #569 out of 918 companies in the Drug Manufacturers industry, placing it in the top 62%.
Is VISEN Pharmaceuticals' PB Ratio too high?
VISEN Pharmaceuticals' current PB Ratio of 2.93 is 10% below median its 10-year median of 3.25. Over the past 10 years, this metric has ranged from a low of 2.47 to a high of 4.89. The Drug Manufacturers industry median PB Ratio is 1.97. VISEN Pharmaceuticals' value of 2.93 is 48.7% above this industry median. Based on the distribution chart, VISEN Pharmaceuticals ranks #569 out of 918 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, VISEN Pharmaceuticals ranks #569 out of 918 companies for PB Ratio. This places VISEN Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.97. VISEN Pharmaceuticals' value of 2.93 is 48.7% above this benchmark. Historically, VISEN Pharmaceuticals' own PB Ratio has ranged from 2.47 to 4.89 over the past decade. While the company's 10-year median is 3.25 vs. the industry median of 1.97, VISEN Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VISEN Pharmaceuticals's current PB Ratio of 2.93 is 48.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on VISEN Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VISEN Pharmaceuticals's current PB Ratio is 2.93, which is 10% below median its own 10-year median of 3.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (HKSE:02561) has a current PB Ratio of 2.93. The current PB Ratio is 2.93, which is 10% below median its 10-year median of 3.25 and 48.7% above the Drug Manufacturers industry median of 1.97. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For VISEN Pharmaceuticals (HKSE:02561), the current PB Ratio is 2.93 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for HKSE:02561
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02561 has been successfully added to your 
